



- (51) International Patent Classification:  
A61K 31/135 (2006.01)
- (21) International Application Number:  
PCT/US2012/059358
- (22) International Filing Date:  
9 October 2012 (09.10.2012)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
61/545,426 10 October 2011 (10.10.2011) US
- (71) Applicant (for all designated States except BB, US):  
**TEVA PHARMACEUTICAL INDUSTRIES LTD.** [IL/IL]; 5 Basel Street, P.O. Box 3190, 49131 Petach Tikva (IL).
- (71) Applicant (for BB only): **TEVA PHARMACEUTICALS USA, INC.** [US/US]; 1090 Horsham Road, North Wales, PA 19454 (US).
- (72) Inventors; and
- (71) Applicants (for US only): **SAFADI, Muhammad** [IL/IL]; Panorama Salezian, 5A, Street 5005, PO Box 385, 16103 Nazareth (IL). **FRENKEL, Anton** [IL/IL]; Amnon ve Tamar Str. 15/10, 42202 Netanya (IL). **KEISAR, Michal** [IL/IL]; 8 Baretet Street, 40300 Kfar-Yona (IL). **LICHT, Danit** [IL/IL]; 1 Keren Hayesod Street, Ramat Ilan, 54041 Givat Shmuel (IL). **BAHAR, Eliezer** [IL/IL]; 95 Halm Levanon Street, 69345 Tel Aviv (IL). **LIDOR-HADAS, Ramy** [IL/IL]; 19 Mor Str., 44242 Kfar-Saba (IL).
- (74) Agent: **WHITE, John, P.**; Cooper & Dunham LLP, 30 Rockefeller Plaza, New York, NY 10112 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— with international search report (Art. 21(3))



(54) Title: R(+)-N-METHYL-PROPARGYL-AMINOINDAN

(57) Abstract: The subject invention provides R(+)-N-methyl-propargylaminoindan or a pharmaceutically acceptable salt thereof and a composition containing R(+)-N-propargyl-1(R)-aminoindan or a pharmaceutically acceptable salt thereof and a compound of R(+)-N-methyl-propargyl-aminoindan or a salt thereof. Also disclosed are methods of validating a batch of rasagiline for use in a pharmaceutical formulation and a method of validating a rasagiline formulation for distribution, based on the content of R(+)-N-methyl-propargyl-aminoindan or a salt thereof.

**R(+)-N-METHYL-PROPARGYL-AMINOINDAN**

This application claims priority of U.S. Provisional  
5 Application No. 61/545,426, filed October 10, 2011, the entire  
content of which is hereby incorporated by reference herein.

Throughout this application various publications, published  
patent applications, and patents are referenced. The  
disclosures of these documents in their entireties are hereby  
10 incorporated by reference into this application in order to  
more fully describe the state of the art to which this  
invention pertains.

**Background of the invention**

15 United States Patents 5,532,415, 5,387,612, 5,453,446,  
5,457,133, 5,599,991, 5,744,500, 5,891,923, 5,668,181,  
5,576,353, 5,519,061, 5,786,390, 6,316,504, 6,630,514,  
7,750,051, and 7,855,233 disclose R(+)-N-propargyl-l-  
aminoindan ("R-PAI"), also known as rasagiline, and its  
20 pharmaceutically acceptable salts. These U.S. patents also  
disclose that rasagiline is a selective inhibitor of the B-  
form of the enzyme monoamine oxidase ("MAO-B") and is useful  
in treating Parkinson's disease and various other conditions  
by inhibition of MAO-B in the brain.

25 United States Patent Nos. 6,126,968, 7,572,834, and 7,598,420,  
United States Patent applications 12/283,022, and 12/283,107  
and PCT publications WO 95/11016 and WO 2006/014973, hereby  
incorporated by reference, disclose pharmaceutical  
30 compositions comprising rasagiline and processes for their  
preparation.

AZILECT<sup>®</sup> is a commercially available rasagiline mesylate  
immediate release formulation indicated for the treatment of  
35 the signs and symptoms of idiopathic Parkinson's disease as  
initial monotherapy and as adjunct therapy to levodopa. The  
current marketed formulation of rasagiline (Azilect<sup>®</sup>) is  
rapidly absorbed, reaching peak plasma concentration ( $t_{max}$ ) in

approximately 1 hour. The absolute bioavailability of rasagiline is about 36%. (AZILECT<sup>®</sup> Product Label, May 2006).

**Summary of the Invention**

The subject invention provides a pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt thereof, citric acid, R(+)-N-methyl-propargyl-aminoindan or a salt thereof, and at least one pharmaceutically acceptable carrier, wherein R(+)-N-methyl-propargyl-aminoindan is present in the composition in an amount greater than about 0.03%, by weight, relative to the amount of rasagiline, based on a determination by an HPLC method.

The subject invention also provides a pharmaceutical composition described herein in tablet form.

The subject invention further provides a process for preparing a pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, comprising:

- a) obtaining a batch of rasagiline or a pharmaceutically acceptable salt thereof;
- b) analyzing the batch for the presence of R(+)-N-methyl-propargyl-aminoindan by a suitable apparatus; and
- c) preparing the pharmaceutical composition from the batch only if the amount of R(+)-N-methyl-propargyl-aminoindan is not more than about 1.0% by weight relative to the amount of rasagiline.

The subject invention yet further provides a process for preparing a packaged pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt thereof comprising:

- a) obtaining a pharmaceutical composition of rasagiline or a pharmaceutically acceptable salt thereof;
- b) analyzing the pharmaceutical composition for the presence of R(+)-N-methyl-propargyl-aminoindan by a suitable apparatus; and
- c) packaging the pharmaceutical composition only if the amount of R(+)-N-methyl-propargyl-aminoindan is not more than about 1.0% by weight relative to the amount of rasagiline.

The subject invention yet further provides a process of distributing a validated batch of a pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier, comprising:

- a) obtaining a batch of the pharmaceutical composition;
- b) performing stability testing with a sample of the batch;
- c) determining the total amount of R(+)-N-methyl-propargyl-aminoindan in the sample of the batch by a suitable apparatus after stability testing;
- d) validating the batch for distribution only if the sample of the batch after stability testing is determined to have not more than about 1.0% by weight of R(+)-N-methyl-propargyl-aminoindan relative to the amount of rasagiline; and
- e) distributing the validated batch.


The subject invention yet further provides R(+)-N-methyl-propargyl-aminoindan or a salt thereof for use, as a reference standard to detect trace amounts of R(+)-N-methyl-propargyl-aminoindan in a pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt of rasagiline.

The subject invention yet further provides a method for treating Parkinson's disease in a patient comprising administering to the patient an amount of the pharmaceutical compositions described herein effective to treat Parkinson's disease in the patient.

30

## Detailed Description of the Invention

R(+)-N-propargyl-1-aminoindan ("R-PAI"), also known as rasagiline, is a small molecule having the following chemical structure:



Rasagiline


Rasagiline has been reported to be a selective inhibitor of the B-form of the enzyme monoamine oxidase ("MAO-B") and is useful in treating Parkinson's disease and various other conditions by inhibition of MAO-B in the brain.

A pharmaceutically acceptable salt of rasagiline, rasagiline citrate, and the process of preparing the same has been described in United States Patent No. 7,855,233, the entire content of which is hereby incorporated by reference.

Crystalline rasagiline, and the process of preparing the same has been described in United States Patent Nos. 7,750,051, 7,968,749, the entire contents of which are hereby incorporated by reference.

Delayed release rasagiline formulations have been described in United States Application Publication Nos. 2009/0181086, 2010/0189790, 2010/0189788, 2010/0189787, and 2010/0189791, the entire content of each of which is hereby incorporated by reference.

It has been found that when rasagiline drug substance or drug product is exposed to certain accelerated conditions, an impurity is formed. This impurity was identified to be R(+)-N-methyl-propargyl-aminoindan, having the following structure:



R(+)-N-methyl-propargyl-aminoindan

5 Other impurities in rasagiline formulations should be avoided, such as rasagiline citramide and R(+)-N-formyl-propargyl-aminoindan.

The subject invention provides a pharmaceutical composition  
10 comprising rasagiline or a pharmaceutically acceptable salt thereof, citric acid, R(+)-N-methyl-propargyl-aminoindan or a salt thereof, and at least one pharmaceutically acceptable carrier, wherein R(+)-N-methyl-propargyl-aminoindan is present in the composition in an amount greater than about 0.03%, by  
15 weight, relative to the amount of rasagiline, based on a determination by an HPLC method.

In an embodiment of the pharmaceutical composition, the amount of R(+)-N-methyl-propargyl-aminoindan is greater than about  
20 0.1%, by weight, relative to the amount of rasagiline, based on a determination by an HPLC method.

In another embodiment of the pharmaceutical composition, the R(+)-N-methyl-propargyl-aminoindan is present in the  
25 pharmaceutical composition in an amount not more than about 1.0%, by weight, relative to the amount of rasagiline, based on a determination by an HPLC method.

In yet another embodiment of the pharmaceutical composition,  
30 the pharmaceutical composition is less than one week old, and the temperature during the less than one week did not exceed ambient temperature.

In yet another embodiment of the pharmaceutical composition, the pharmaceutical composition comprises rasagiline as free base.

5

In yet another embodiment of the pharmaceutical composition, the pharmaceutical composition comprises the pharmaceutically acceptable salt of rasagiline, and which salt is rasagiline citrate.

10

In yet another embodiment of the pharmaceutical composition, the pharmaceutical composition is a solid pharmaceutical composition.

15 In yet another embodiment of the pharmaceutical composition, the pharmaceutical composition is in tablet form.

In an embodiment of the pharmaceutical composition in tablet form, the tablet has a core and a coating, wherein the core of the tablet comprises an amount of rasagiline as free base, citric acid and mannitol.

25 In another embodiment of the pharmaceutical composition in tablet form, in the core of the tablet the weight ratio of mannitol to citric acid is between 45 to 1 and 10 to 1.

In yet another embodiment of the pharmaceutical composition in tablet form, in the core of the tablet the weight ratio of mannitol to citric acid is between 30 to 1 and 25 to 1.

30

In yet another embodiment of the pharmaceutical composition in tablet form, the tablet has a core and a coating, wherein the core of the tablet comprises an amount of rasagiline and citric acid, about 59.9% of mannitol, about 0.53% of aerosil, about 6.6% of starch NF, about 26.3% of pregelatinized starch, about 2.0% of stearic acid, and about 2.0% of talc, by weight, relative to the weight of the core of the tablet.

35

In yet another embodiment of the pharmaceutical composition in

tablet form, the tablet comprises an amount of rasagiline and citric acid, 45.5 mg of mannitol, 0.4 mg of aerosil, 5.0 mg of starch NF, 20.0 mg of pregelatinized starch, 1.5 mg of stearic acid, 1.5 mg of talc, and the coating of the tablet comprises  
5 two coating layers, of which the inner of the two coating layers comprises 3.5 mg of hypromellose and the outer of the two coating layers comprises 4.0 mg of methacrylic acid ethyl acrylate copolymer, 0.8 mg of triethyl citrate, and 1.9 mg of talc extra fine.

10

In yet another embodiment of the pharmaceutical composition in tablet form, the amount of rasagiline in the core is 0.5 mg.

In yet another embodiment of the pharmaceutical composition in  
15 tablet form, the tablet has a core and a coating, wherein the core of the tablet comprises an amount of rasagiline and citric acid, about 59.2% of mannitol, about 0.53% of aerosil, about 6.6% of starch NF, about 26.3% of pregelatinized starch, about 2.0% of stearic acid, and about 2.0% of talc, by weight,  
20 relative to the weight of the core of the tablet.

In yet another embodiment of the pharmaceutical composition in tablet form, the core of the tablet comprises an amount of rasagiline and citric acid, 45.0 mg of mannitol, 0.4 mg of  
25 aerosil, 5.0 mg of starch NF, 20.0 mg of pregelatinized starch, 1.5 mg of stearic acid, 1.5 mg of talc, and the coating of the tablet comprises two coating layers, of which the inner of the two coating layers comprises 3.5 mg of hypromellose and the outer of the two coating layers comprises  
30 4.0 mg of methacrylic acid ethyl acrylate copolymer, 0.8 mg of triethyl citrate, and 1.9 mg of talc extra fine.

In yet another embodiment of the pharmaceutical composition in tablet form, the amount of rasagiline in the core is 1.0 mg.

35

In yet another embodiment of the pharmaceutical, not more than 1.0% by weight of rasagiline citramide or a salt thereof is in the pharmaceutical composition relative to the amount of rasagiline.

In yet another embodiment of the pharmaceutical composition, not more than about 1.0% by weight of R(+)-N-formyl-propargyl-aminoindan or a salt thereof is in the pharmaceutical composition relative to the amount of rasagiline.

In yet another embodiment of the pharmaceutical composition, not more than about 0.5% by weight of R(+)-N-formyl-propargyl-aminoindan or a salt thereof is in the pharmaceutical composition relative to the amount of rasagiline.

The subject invention further provides a process for preparing a pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, comprising:

- a) obtaining a batch of rasagiline or a pharmaceutically acceptable salt thereof;
- b) analyzing the batch for the presence of R(+)-N-methyl-propargyl-aminoindan by a suitable apparatus; and
- c) preparing the pharmaceutical composition from the batch only if the amount of R(+)-N-methyl-propargyl-aminoindan is not more than about 1.0% by weight relative to the amount of rasagiline.

The subject invention yet further provides a process for preparing a packaged pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt thereof comprising:

- a) obtaining a pharmaceutical composition of rasagiline or a pharmaceutically acceptable salt thereof;
- b) analyzing the pharmaceutical composition for the presence of R(+)-N-methyl-propargyl-aminoindan by a suitable apparatus; and
- c) packaging the pharmaceutical composition only if the amount of R(+)-N-methyl-propargyl-aminoindan is not more than about 1.0% by weight relative to the amount of rasagiline.

The subject invention yet further provides a process of distributing a validated batch of a pharmaceutical composition

comprising rasagiline or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier, comprising:

- a) obtaining a batch of the pharmaceutical composition;
- 5 b) performing stability testing with a sample of the batch;
- c) determining the total amount of R(+)-N-methyl-propargyl-aminoindan in the sample of the batch by a suitable apparatus after stability testing;
- d) validating the batch for distribution only if the sample  
10 of the batch after stability testing is determined to have not more than about 1.0% by weight of R(+)-N-methyl-propargyl-aminoindan relative to the amount of rasagiline; and
- e) distributing the validated batch.

15 In an embodiment of any of the processes disclosed herein, the pharmaceutical composition comprises rasagiline free base.

In an embodiment of any of the processes disclosed herein, the pharmaceutical composition comprises rasagiline citrate.

20

The subject invention yet further provides the use of R(+)-N-methyl-propargyl-aminoindan or a salt thereof, as a reference standard to detect trace amounts of R(+)-N-methyl-propargyl-aminoindan in a pharmaceutical composition comprising  
25 rasagiline or a pharmaceutically acceptable salt of rasagiline.

The subject invention yet further provides a method for treating Parkinson's disease in a patient comprising  
30 administering to the patient an amount of the pharmaceutical compositions disclosed herein effective to treat Parkinson's disease in the patient.

Every embodiment disclosed herein can be combined with every  
35 other embodiment of the subject invention, unless specified otherwise.

By any range disclosed herein, it is meant that all hundredth, tenth and integer unit amounts within the range are

specifically disclosed as part of the invention. Thus, for example, 0.01 mg to 50 mg means that 0.02, 0.03 ... 0.09; 0.1, 0.2 ... 0.9; and 1, 2 ... 49 mg unit amounts are included as embodiments of this invention.

5

It will be noted that the structure of the compounds of this invention includes an asymmetric carbon atom and thus the compounds occur as racemates, racemic mixtures, and isolated single enantiomers. All such isomeric forms of these compounds are expressly included in this invention. Each stereogenic carbon may be of the R or S configuration. It is to be understood accordingly that the isomers arising from such asymmetry (e.g., all enantiomers and diastereomers) are included within the scope of this invention, unless indicated otherwise. Such isomers can be obtained in substantially pure form by classical separation techniques and by stereochemically controlled synthesis, such as those described in "Enantiomers, Racemates and Resolutions" by J. Jacques, A. Collet and S. Wilen, Pub. John Wiley & Sons, NY, 1981. For example, the resolution may be carried out by preparative chromatography on a chiral column.

The subject invention is also intended to include all isotopes of atoms occurring on the compounds disclosed herein. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include tritium and deuterium. Isotopes of carbon include C-13 and C-14.

It will be noted that any notation of a carbon in structures throughout this application, when used without further notation, are intended to represent all isotopes of carbon, such as  $^{12}\text{C}$ ,  $^{13}\text{C}$ , or  $^{14}\text{C}$ . Furthermore, any compounds containing  $^{13}\text{C}$  or  $^{14}\text{C}$  may specifically have the structure of any of the compounds disclosed herein.

It will also be noted that any notation of a hydrogen in structures throughout this application, when used without further notation, are intended to represent all isotopes of

hydrogen, such as  $^1\text{H}$ ,  $^2\text{H}$ , or  $^3\text{H}$ . Furthermore, any compounds containing  $^2\text{H}$  or  $^3\text{H}$  may specifically have the structure of any of the compounds disclosed herein.

5 Isotopically-labeled compounds can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the Examples disclosed herein using an appropriate isotopically-labeled reagents in place of the non-labeled reagents employed.

10

A characteristic of a compound refers to any quality that a compound exhibits, e.g., peaks or retention times, as determined by  $^1\text{H}$  nuclear magnetic spectroscopy, mass spectroscopy, infrared, ultraviolet or fluorescence  
15 spectrophotometry, gas chromatography, thin layer chromatography, high performance liquid chromatography (HPLC), elemental analysis, Ames test, dissolution, stability and any other quality that can be determined by an analytical method. Once the characteristics of a compound are known, the  
20 information can be used to, for example, screen or test for the presence of the compound in a sample. Quantity or weight percentage of a compound present in a sample can be determined by a suitable apparatus, for example, a HPLC.

25 As used herein, a "pharmaceutically acceptable salt" of rasagiline includes citrate, tannate, malate, mesylate, maleate, fumarate, tartrate, esylate, p-toluenesulfonate, benzoate, acetate, phosphate and sulfate salts. For the preparation of pharmaceutically acceptable acid addition salts  
30 of the compounds of the invention, the free base can be reacted with the desired acids in the presence of a suitable solvent by conventional methods.

Rasagiline can also be used in its free base form. A process  
35 of manufacture of the rasagiline free base is described in U.S. Patent Nos. 7,750,051 and 7,968,749, the contents of which are hereby incorporated by reference.

As used herein, "drug substance" refers to the active

ingredient in a drug product, which provides pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of man or animals.

5

As used herein, "drug product" refers to the finished dosage form containing the drug substance as well as at least one pharmaceutically acceptable carrier.

10 As used herein, an "isolated" compound is a compound isolated from the crude reaction mixture following an affirmative act of isolation. The act of isolation necessarily involves separating the compound from the other known components of the crude reaction mixture, with some impurities, unknown side  
15 products and residual amounts of the other known components of the crude reaction mixture permitted to remain. Purification is an example of an affirmative act of isolation.

As used herein, a composition that is "free" of a chemical  
20 entity means that the composition contains, if at all, an amount of the chemical entity which cannot be avoided following an affirmative act intended to purify the composition by separating the chemical entity from the composition.

25

As used herein, "stability testing" refers to tests conducted at specific time intervals and various environmental conditions (e.g., temperature and humidity) to see if and to what extent a drug product degrades over its designated shelf  
30 life time. The specific conditions and time of the tests are such that they accelerate the conditions the drug product is expected to encounter over its shelf life. For example, detailed requirements of stability testing for finished pharmaceuticals are codified in 21 C.F.R §211.166, the entire  
35 content of which is hereby incorporated by reference.

As used herein, a pharmaceutical composition which is "X weeks old" refers to the period of time, in this case one week, since the pharmaceutical composition was made.

As used herein, "ambient temperature" refers a temperature of from about 20°C to about 30°C.

5 A "detection limit" for an analytical method used in screening or testing for the presence of a compound in a sample is a threshold under which the compound in a sample cannot be detected by the analytical method, e.g. an HPLC, MS, NMR, or FT-IR method.

10

As used herein, "about" in the context of a measurable numerical value means the numerical value within the standard error of the analytical method used to measure.

15 A dosage unit may comprise a single compound or mixtures of compounds thereof. A dosage unit can be prepared for oral dosage forms, such as tablets, capsules, pills, powders, and granules.

20 As used herein, a "pharmaceutically acceptable" carrier or excipient is one that is suitable for use with humans and/or animals without undue adverse side effects (such as toxicity, irritation, and allergic response) commensurate with a reasonable benefit/risk ratio.

25

Specific examples of pharmaceutical acceptable carriers and excipients that may be used to formulate oral dosage forms are described, e.g., in U.S. Pat. No. 6,126,968 to Peskin et al., issued Oct. 3, 2000. Techniques and compositions for making  
30 dosage forms useful in the present invention are described in the following references: 7 Modern Pharmaceutics, Chapters 9 and 10 (Banker & Rhodes, Editors, 1979); Pharmaceutical Dosage Forms: Tablets (Lieberman et al., 1981); Ansel, Introduction to Pharmaceutical Dosage Forms 2nd Edition (1976); Remington's  
35 Pharmaceutical Sciences, 17th ed. (Mack Publishing Company, Easton, Pa., 1985); Advances in Pharmaceutical Sciences (David Ganderton, Trevor Jones, Eds., 1992); Advances in Pharmaceutical Sciences Vol 7. (David Ganderton, Trevor Jones, James McGinity, Eds., 1995); Aqueous Polymeric Coatings for

Pharmaceutical Dosage Forms (Drugs and the Pharmaceutical Sciences, Series 36 (James McGinity, Ed., 1989); Pharmaceutical Particulate Carriers: Therapeutic Applications: Drugs and the Pharmaceutical Sciences, Vol 61 (Alain Rolland, Ed., 1993); Drug Delivery to the Gastrointestinal Tract (Ellis Horwood Books in the Biological Sciences. Series in Pharmaceutical Technology; J. G. Hardy, S. S. Davis, Clive G. Wilson, Eds.); Modern Pharmaceutics Drugs and the Pharmaceutical Sciences, Vol 40 (Gilbert S. Banker, Christopher T. Rhodes, Eds.).

Tablets may contain suitable binders, lubricants, disintegrating agents, coloring agents, flavoring agents, flow-inducing agents, melting agents, stabilizing agents, solubilizing agents, antioxidants, buffering agent, chelating agents, fillers and plasticizers. For instance, for oral administration in the dosage unit form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as gelatin, agar, starch, methyl cellulose, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like. Suitable binders include starch, gelatin, natural sugars such as corn starch, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, povidone, carboxymethylcellulose, polyethylene glycol, waxes, and the like. Antioxidants include ascorbic acid, fumaric acid, citric acid, malic acid, gallic acid and its salts and esters, butylated hydroxyanisole, editic acid. Lubricants used in these dosage forms include sodium oleate, sodium stearate, sodium benzoate, sodium acetate, stearic acid, sodium stearyl fumarate, talc and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum, croscarmellose sodium, sodium starch glycolate and the like, suitable plasticizers include triacetin, triethyl citrate, dibutyl sebacate, polyethylene glycol and the like.

This invention will be better understood by reference to the Experimental Details which follow, but those skilled in the art will readily appreciate that the specific experiments

detailed are only illustrative of the invention as described more fully in the claims which follow thereafter.

**Experimental Details:**Example 1 - Stability Study of Rasagiline Base Drug Substance:

Rasagiline base drug substance was subject to stability testing under various storage conditions. Rasagiline base drug substance was prepared according to procedures described in Examples 1-3 of United States Patent No. 7,968,749.

The observed melting point of Rasagiline base is 38-41°C so it appears as a liquid melt at elevated temperatures. This is the reason for performing the degradation study of rasagiline base at 78°C - 90°C in melt phase.

Samples of Rasagiline base were introduced into amber glass vials, closed with stoppers and covered with aluminium foil for protection from light. Samples intended to degrade under an inert atmosphere were flushed with nitrogen for 5 minutes before closing with a stopper.

The samples were introduced into a pre-heated oven and held at a constant temperature of 78 and 90°C for 24, 72 or 137 hrs. After completion of the treatment the samples were refrigerated and analyzed. The results are summarized in Table 1 below which shows that no R(+)-N-methyl-PAI was formed.

Table 1. Rasagiline base degradation in melt phase

Exp. No.	Atm.	Temp.	Time	R(+)-N-methyl-PAI, % of Rasagiline
		deg. C	hrs	
1	N <sub>2</sub>	78	24	N.A.
2	N <sub>2</sub>	78	72	N.A.
3	Air	78	24	N.A.
4	Air	78	72	N.A.
5	Air	90	24	N.D.
6	Air	90	72	N.D.
7	Air	90	137	N.D.

N.D. - not detected

N.A. - not available

R(+)-N-methyl-PAI was monitored in the drug products during the stability study and was found in the validation batches after 6 months storage at accelerated conditions (40°C/75%RH) at the 0.1% (the Quantitation Level) for the 0.5 mg formulation and at levels of up to 0.3% for the 1 mg formulation. It was not seen in any batch after 12 months under real-time storage conditions (25°C/60%RH).

10

Example 2: Preparation of R(+)-N-methyl-propargyl-aminoindan

R(+)-N-methyl-PAI HCl can be synthesized by methylation of R(+)-PAI and can be isolated as crystalline hydrochloride salt.

15

For example, a method for preparing hydrochloride salt of R(+)-N-methyl-PAI has been described in U.S. Patent No. 5,744,500, the entire content of which is incorporated by reference.

20

As described in U.S. Patent No. 5,744,500, 1.2 g of R(+)-PAI free base, 0.97 g of potassium carbonate and 1 g of methyl iodide were added to 15 ml of acetone and the resulting suspension was heated to reflux under a nitrogen atmosphere for 8 hours. The volatiles were then removed under reduced pressure and the residue partitioned between 10% aqueous sodium hydroxide (30 ml) and methylene chloride (30 ml). The organic phase was dried by removing the solvent in vacuo. The residue was flash chromatographed on silica gel eluting with 40% ethyl acetate/60% hexane. Fractions containing R(+)-N-methyl-PAI free base were combined and the solvent was replaced by diethyl ether. The ethereal solution was then treated with gaseous HCl and the volatiles were removed in vacuo. The residue recrystallized from isopropanol to yield 400 mg of R(+)-N-methyl-PAI HCl as a white crystalline solid, m.p. 134-136°C,  $[\alpha]_D^{25} +31.40$  (ethanol). NMR  $\delta$  (CDCl<sub>3</sub>): 2.55 (2H,m); 2.7 (1H,br.s); 2.8 (3H,s); 3.0 (1H,m); 3.4 (1H,m); 3.9 (2H,br.s); 5.05 (1H,m); 7.7(4H,m) ppm.

R(+)-N-methyl-PAI HCl was characterized by elemental analysis, HPLC, <sup>1</sup>H-NMR, <sup>13</sup>C-NMR, ATR and MS.

## 5 **Elemental Analysis**

The analysis for C, H and N was performed using a Perkin-Elmer 2400 series II analyzer. Analysis for Cl was performed using the oxygen-flask combustion method (Schoniger application) and subsequent potentiometric titration by the 835 Titrande  
10 Metrohm Tiroprocessor.

### **Element Analysis Results for R(+)-N-Methyl-PAI HCl**

Element	%C	%H	%N	%Cl
Theoretical	70.42	7.27	6.32	15.99
Experimental	70.27	7.20	6.29	16.38

The results of the elemental analysis correspond to the  
15 molecular formula.


### **HPLC Chromatogram**

The prepared R(+)-N-methyl-PAI elutes at good chromatographic purity (99.67% area in a HPLC chromatogram).  
20

### **NMR Spectroscopy**

The <sup>1</sup>H-NMR and <sup>13</sup>C-NMR spectra of R(+)-N-methyl-PAI hydrochloride were recorded on a Bruker 300 MHz NMR instrument at 300.1 and 75.5 MHz respectively. The spectra were run at  
25 room temperature (T = 300K) in DMSO-D<sub>6</sub> as a solvent with TMS as internal reference. The shift assignments are summarized in Table 2. The spectra are fully consistent with the expected structure.

STRUCTURE OF R(+)-N-ME-PAI HCL WITH DESIGNATIONS USED FOR THE ATTRIBUTION OF  $^1\text{H}$ -NMR AND  $^{13}\text{C}$ -NMR SHIFTS



5

Table 2.  $^1\text{H}$ -NMR and  $^{13}\text{C}$ -NMR Chemical Shifts of N-Me-PAI HCl in DMSO- $\text{D}_6$  at T=300K

	$^{13}\text{C}$ (ppm)	$^1\text{H}$ (ppm)	Multiplicity <sup>1</sup>
C#1	67.56 & 68.00	1H 5.06, 5.11	2 brm
C#2	24.07 & 24.57	2H 2.30-2.60	brs (with DMSO)
C#3	30.14	1H 2.90 1H 3.14	brm brm
C#4	145.31 & 146.13	-----	-----
C#5	129.74	3H 7.25-7.45	brm
C#6	125.17		
C#7	126.70		
C#8	127.12	1H 8.1, 7.91	2 brm
C#9	134.58 & 135.46	-----	-----
C#10	40.95 & 42.96	2H 4.08	brm
C#11	80.99	-----	-----
C#12	73.73	1H 2.51, 2.66	brm (with DMSO)
C#13	34.14 & 36.62	3H 3.41, 3.86	brs
NH	-----	1H 12.08	brs

<sup>1</sup> brs= broad singlet; brm = broad multiplet

## 10 ATR Spectrum

The FT-IR (using ATR) spectrum of R(+)-N-methyl-PAI hydrochloride was measured with a Thermo Scientific Nicolet 6700 FT-IR apparatus. The IR spectrum exhibits typical absorption bands of acetylene vibration at 2120 and 3201.

15

## Mass Spectroscopy (MS)

The mass spectrum of R(+)-N-methyl-PAI hydrochloride was performed on AB Applied Biosystems Sciex API 4000 LC/MS/MS

system.

The mass spectrum exhibits quasi-molecular ions at  $m/z$  181  $[M+H^+]$  and fragmentation ions at 39; 70; 91 and 117. The  
5 spectrum is in agreement with the molecular formula of R(+)-N-methyl-PAI.

**What is claimed is:**

1. A pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt thereof, citric acid, R(+)-N-methyl-propargyl-aminoindan or a salt thereof, and at least one pharmaceutically acceptable carrier, wherein R(+)-N-methyl-propargyl-aminoindan is present in the composition in an amount greater than about 0.03%, by weight, relative to the amount of rasagiline, based on a determination by an HPLC method.
2. The pharmaceutical composition of claim 1, wherein the amount of R(+)-N-methyl-propargyl-aminoindan is greater than about 0.1%, by weight, relative to the amount of rasagiline, based on a determination by an HPLC method.
3. The pharmaceutical composition of claim 1 or 2, wherein the R(+)-N-methyl-propargyl-aminoindan is present in the pharmaceutical composition in an amount not more than about 1.0%, by weight, relative to the amount of rasagiline, based on a determination by an HPLC method.
4. The pharmaceutical composition of any one of claims 1-3, wherein the pharmaceutical composition is less than one week old, and the temperature during the less than one week did not exceed ambient temperature.
5. The pharmaceutical composition of any one of claims 1-4, which comprises rasagiline as free base.
6. The pharmaceutical composition of any one of claims 1-4, which comprises the pharmaceutically acceptable salt of rasagiline, and which salt is rasagiline citrate.
7. The pharmaceutical composition of any one of claims 1-6, wherein the pharmaceutical composition is a solid pharmaceutical composition.

8. The pharmaceutical composition of claim 7, which is in tablet form.
9. The pharmaceutical composition of claim 8 having a core and a coating, wherein the core of the tablet comprises an amount of rasagiline free base, citric acid and mannitol.
10. The pharmaceutical composition of claim 9 wherein in the core of the tablet the weight ratio of mannitol to citric acid is between 45 to 1 and 10 to 1.
11. The pharmaceutical composition of claim 10 wherein in the core of the tablet the weight ratio of mannitol to citric acid is between 30 to 1 and 25 to 1.
12. The pharmaceutical composition of any one of claims 8-11 having a core and a coating, wherein the core of the tablet comprises an amount of rasagiline and citric acid, about 59.9% of mannitol, about 0.53% of aerosil, about 6.6% of starch NF, about 26.3% of pregelatinized starch, about 2.0% of stearic acid, and about 2.0% of talc, by weight, relative to the weight of the core of the tablet.
13. The pharmaceutical composition of claim 12, wherein the core of the tablet comprises an amount of rasagiline and citric acid, 45.5 mg of mannitol, 0.4 mg of aerosil, 5.0 mg of starch NF, 20.0 mg of pregelatinized starch, 1.5 mg of stearic acid, 1.5 mg of talc, and the coating of the tablet comprises two coating layers, of which the inner of the two coating layers comprises 3.5 mg of hypromellose and the outer of the two coating layers comprises 4.0 mg of methacrylic acid ethyl acrylate copolymer, 0.8 mg of triethyl citrate, and 1.9 mg of talc extra fine.
14. The pharmaceutical composition of any one of claims 9-13, wherein the amount of rasagiline in the core is 0.5 mg.

15. The pharmaceutical composition of any one of claims 8-11 having a core and a coating, wherein the core of the tablet comprises an amount of rasagiline and citric acid, about 59.2% of mannitol, about 0.53% of aerosil, about 6.6% of starch NF, about 26.3% of pregelatinized starch, about 2.0% of stearic acid, and about 2.0% of talc, by weight, relative to the weight of the core of the tablet.
16. The pharmaceutical composition of claim 15, wherein the core of the tablet comprises an amount of rasagiline and citric acid, 45.0 mg of mannitol, 0.4 mg of aerosil, 5.0 mg of starch NF, 20.0 mg of pregelatinized starch, 1.5 mg of stearic acid, 1.5 mg of talc, and the coating of the tablet comprises two coating layers, of which the inner of the two coating layers comprises 3.5 mg of hypromellose and the outer of the two coating layers comprises 4.0 mg of methacrylic acid ethyl acrylate copolymer, 0.8 mg of triethyl citrate, and 1.9 mg of talc extra fine.
17. The pharmaceutical composition of any one of claims 9-11, 15 or 16, wherein the amount of rasagiline in the core is 1.0 mg.
18. The pharmaceutical composition of any one of claims 1-17, wherein not more than 1.0% by weight of rasagiline citramide or a salt thereof is in the pharmaceutical composition relative to the amount of rasagiline.
19. The pharmaceutical composition of any one of claims 1-18, wherein not more than about 1.0% by weight of R(+)-N-formyl-propargyl-aminoindan or a salt thereof is in the pharmaceutical composition relative to the amount of rasagiline.
20. The pharmaceutical composition of claim 19, wherein not more than about 0.5% by weight of R(+)-N-formyl-propargyl-aminoindan or a salt thereof is in the

pharmaceutical composition relative to the amount of rasagiline.

21. A process for preparing a pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, comprising:
  - a) obtaining a batch of rasagiline or a pharmaceutically acceptable salt thereof;
  - b) analyzing the batch for the presence of R(+)-N-methyl-propargyl-aminoindan by a suitable apparatus; and
  - c) preparing the pharmaceutical composition from the batch only if the amount of R(+)-N-methyl-propargyl-aminoindan is not more than about 1.0% by weight relative to the amount of rasagiline.
  
22. A process for preparing a packaged pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt thereof comprising:
  - a) obtaining a pharmaceutical composition of rasagiline or a pharmaceutically acceptable salt thereof;
  - b) analyzing the pharmaceutical composition for the presence of R(+)-N-methyl-propargyl-aminoindan by a suitable apparatus; and
  - c) packaging the pharmaceutical composition only if the amount of R(+)-N-methyl-propargyl-aminoindan is not more than about 1.0% by weight relative to the amount of rasagiline.
  
23. A process of distributing a validated batch of a pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier, comprising:
  - a) obtaining a batch of the pharmaceutical composition;
  - b) performing stability testing with a sample of the batch;

- c) determining the total amount of R(+)-N-methyl-propargyl-aminoindan in the sample of the batch by a suitable apparatus after stability testing;
  - d) validating the batch for distribution only if the sample of the batch after stability testing is determined to have not more than about 1.0% by weight of R(+)-N-methyl-propargyl-aminoindan relative to the amount of rasagiline; and
  - e) distributing the validated batch.
24. The process of any one of claims 21-23, wherein the pharmaceutical composition comprises rasagiline free base.
25. The process of any one of claims 21-23, wherein the pharmaceutical composition comprises rasagiline citrate.
26. R(+)-N-methyl-propargyl-aminoindan or a salt thereof for use, as a reference standard to detect trace amounts of R(+)-N-methyl-propargyl-aminoindan in a pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt of rasagiline.
27. A method for treating Parkinson's disease in a patient comprising administering to the patient an amount of the pharmaceutical composition of any one of claims 1-20 effective to treat Parkinson's disease in the patient.

INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 12/59358

<p><b>A. CLASSIFICATION OF SUBJECT MATTER</b>                  IPC(8) - A61K 31/135 (2012.01)                  USPC - 514/647                  According to International Patent Classification (IPC) or to both national classification and IPC</p>														
<p><b>B. FIELDS SEARCHED</b></p> <p>Minimum documentation searched (classification system followed by classification symbols)                  IPC(8): A61K 31/135 (2012.01)                  USPC: 514/647 (text search)</p> <p>Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched                  USPC: 514/657; 564/308 (text search) Find search terms below</p> <p>Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)                  PubWEST (PGPB,USPT,USOC,EPAB,JPAB), Google Scholar, PatBase, SureChem                  rasagiline, N-propargyl aminoindan, N-methyl, N-methylated, N-methyl-N-propargyl\$aminoindan, pharmaceutical composition, formulation, citric acid</p>														
<p><b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b></p> <table border="1"> <thead> <tr> <th>Category*</th> <th>Citation of document, with indication, where appropriate, of the relevant passages</th> <th>Relevant to claim No.</th> </tr> </thead> <tbody> <tr> <td>Y</td> <td>US 2010/0189787 A1 (SAFADI et al.) 29 July 2010 (29.07.2010) para [0006]-[0007], [0092]-[0130], [0154]-[0163], [0367]</td> <td>1-3 and 21-26</td> </tr> <tr> <td>Y</td> <td>US 2006/0094783 A1 (YOU DIM et al.) 04 May 2006 (04.05.2006) para [0013], [0160], [0178]-[0183], Table 1A; Table 1B</td> <td>1-3 and 21-26</td> </tr> <tr> <td>A</td> <td>US 2010/0168239 A1 (POEWE) 01 July 2010 (01.07.2010) para [0024]-[0073]</td> <td>1-3 and 21-26</td> </tr> </tbody> </table>			Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	Y	US 2010/0189787 A1 (SAFADI et al.) 29 July 2010 (29.07.2010) para [0006]-[0007], [0092]-[0130], [0154]-[0163], [0367]	1-3 and 21-26	Y	US 2006/0094783 A1 (YOU DIM et al.) 04 May 2006 (04.05.2006) para [0013], [0160], [0178]-[0183], Table 1A; Table 1B	1-3 and 21-26	A	US 2010/0168239 A1 (POEWE) 01 July 2010 (01.07.2010) para [0024]-[0073]	1-3 and 21-26
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.												
Y	US 2010/0189787 A1 (SAFADI et al.) 29 July 2010 (29.07.2010) para [0006]-[0007], [0092]-[0130], [0154]-[0163], [0367]	1-3 and 21-26												
Y	US 2006/0094783 A1 (YOU DIM et al.) 04 May 2006 (04.05.2006) para [0013], [0160], [0178]-[0183], Table 1A; Table 1B	1-3 and 21-26												
A	US 2010/0168239 A1 (POEWE) 01 July 2010 (01.07.2010) para [0024]-[0073]	1-3 and 21-26												
<p><input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/></p>														
<p>* Special categories of cited documents:</p> <table border="0"> <tr> <td>“A” document defining the general state of the art which is not considered to be of particular relevance</td> <td>“T” later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>“E” earlier application or patent but published on or after the international filing date</td> <td>“X” document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>“L” document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>“Y” document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>“O” document referring to an oral disclosure, use, exhibition or other means</td> <td>“&amp;” document member of the same patent family</td> </tr> <tr> <td>“P” document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </table>			“A” document defining the general state of the art which is not considered to be of particular relevance	“T” later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	“E” earlier application or patent but published on or after the international filing date	“X” document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	“L” document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	“Y” document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	“O” document referring to an oral disclosure, use, exhibition or other means	“&” document member of the same patent family	“P” document published prior to the international filing date but later than the priority date claimed			
“A” document defining the general state of the art which is not considered to be of particular relevance	“T” later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention													
“E” earlier application or patent but published on or after the international filing date	“X” document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone													
“L” document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	“Y” document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art													
“O” document referring to an oral disclosure, use, exhibition or other means	“&” document member of the same patent family													
“P” document published prior to the international filing date but later than the priority date claimed														
<p>Date of the actual completion of the international search 23 November 2012 (23.11.2012)</p>		<p>Date of mailing of the international search report <b>06 DEC 2012</b></p>												
<p>Name and mailing address of the ISA/US                  Mail Stop PCT, Attn: ISA/US, Commissioner for Patents                  P.O. Box 1450, Alexandria, Virginia 22313-1450                  Facsimile No. 571-273-3201</p>		<p>Authorized officer:                  Lee W. Young                  PCT Helpdesk: 571-272-4300                  PCT OSP: 571-272-7774</p>												

INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 12/59358

**Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

- 1.  Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
- 2.  Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
- 3.  Claims Nos.: 4-20 and 27  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

- 1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
- 2.  As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
- 3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
- 4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.